Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults

NCT04537949 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04537949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04537949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Completed
Start date
September 9, 2020
Completion date
February 7, 2022
Enrollment
96 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, protection against covid-19